Cancer Immunotherapy Conference Agenda

 

Day 1

 

7:30

Registration

8:00

Opening Remarks

8:15

Keynote Address: Immunotherapy: Making the Immune System Great Again

James Gulley, M.D., Ph.D.
Chief–Genitourinary Malignancies Branch;
Director–Medical Oncology Service
Center for Cancer Research, NIH

Session I

Therapeutic Vaccines

9:00

The Evolving Role of Cancer Vaccines

Col. (ret.) George E. Peoples, M.D., FACS, MC, USA
Founder and CEO, Cancer Insight, LLC;
Director–Cancer Vaccine Development Program;
Professor of Surgery, Uniformed Services University;
Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center

9:20

In Situ Vaccination to Potential Checkpoint Blockade: Optimizing Cross-Presentation in Mouse and Man. And Woman

Joshua Brody, M.D.
Director–Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai,
Hess Center for Science and Medicine

9:40

AutoSynVax Overview

Robert Stein, M.D., Ph.D.
President–Research and Development and CSO
Agenus

9:50

pLADD Overview

Thomas W. Dubensky, Jr., Ph.D.

Chief Scientific Officer
Aduro Biotech

10:00

Therapeutic Vaccine Panel Discussion

10:45

Break


 

Session II

Immunomodulators

11:00

Immunotherapy: What’s Genes Got to Do With It?

Timothy Chan M.D., Ph.D.

Vice Chair, Department of Radiation Oncology;

Director–Translational Oncology Division;

Member–Human Oncology & Pathogenesis Program;

Director–Immunogenomics and Precision Oncology Platform;

Paine Webber Chair in Cancer Genetics

Memorial Sloan Kettering Cancer Center

11:15

Direct Activation of STING for Cancer Immunotherapy

Thomas W. Dubensky, Jr., Ph.D.

Chief Scientific Officer
Aduro Biotech

11:30

NKTR-214, a T-cell Growth Engine for Immuno-Oncology

Deborah Charych, Ph.D.

Executive Director–Research and Development

Nektar Therapeutics

11:45

Systematic Targeting of Immune Cells to Treat Cancer

Robert Sikorski, M.D., Ph.D.
Senior Vice President and Chief Medical Officer
Five Prime Therapeutics

12:00

TLR9 Agonists in Cancer Immunotherapy

Robert Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer
Dynavax

12:15

Lunch

1:00

Immunomodulator Panel Discussion


 

Session III

Adoptive Cell Therapies

1:55

CD19-Targeted Car-T Cells: Past, Present, & Future

Marco Davila, M.D., Ph.D.

Associate Member, Department of Blood and Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

2:10

TCRs for Solid Tumors

Helen Tayton-Martin, Ph.D.

Chief Operating Officer

Adaptimmune

2:25

Synthetic Regulation of T Cells

David Spencer, Ph.D.

Chief Scientific Officer

Bellicum Pharmaceuticals

2:40

HPV Targeted T-Cells for HPV Associated Cancers

Christian Hinrichs M.D.

Investigator, Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, Center for Cancer Research

National Cancer Institute

2:55

Break

3:15

Allogeneic CAR-T Therapy

André Choulika, Ph.D.

Chief Executive Officer

Cellectis

3:30

Title to be Determined

 

Christian Itin, Ph.D.

Chief Executive Officer

Autolus

3:45

Adoptive Cell Therapy Panel Discussion

5:00

Reception


 

Day 2

 

7:30

Registration

8:15

Keynote Address: Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms

Jedd Wolchok, M.D., Ph.D.

Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma & Immunotherapeutics Service; Director–Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center; Associate Director–Ludwig Center for Cancer Immunotherapy; Member–Ludwig Cancer Research; Professor of Medicine, Weill Medical College of Cornell University

Session IV

Immunotherapy Combination Approaches

9:00

Title to Be Determined

Bristol-Myers Squibb

9:20

Targeting the Tumor Microenvironment in Combination with Checkpoint Inhibitors

Miriam Merad, M.D., Ph.D.

Professor of Medicine, Hematology, and Medical Oncology

Mount Sinai

9:40

Immunotherapy Combinations: Science Informing Clinical Studies

 

Christoffer Boshoff, M.D., Ph.D.

Senior Vice President, Immuno-Oncology, Early Development and Translational Oncology

Pfizer Inc.

10:00

Break


 

10:20

Title to Be Determined

Jeffery Kutok, M.D., Ph.D.

Chief Scientific Officer

Infinity Pharmaceuticals

10:40

Title to Be Determined

Eric Hedrick, M.D.

Clinical Advisor

BeiGene

11:00

Emerging Next Generation Checkpoint Modulators

Robert Stein, M.D., Ph.D.
President—Research and Development and
Chief Scientific Officer
Agenus

11:20

Development of Rational Combinations in Immuno-oncology

Michael Kalos, Ph.D.
Chief Scientific Officer, Cancer Immunobiology
Lilly Research Laboratories, Eli Lilly & Company

11:40

Lunch Presentation  and Panel Discussions by INC Research

 

Laura Vidal, M.D.

Senior Medical Director-Global Oncology & Hematology

INC Research

1:00

Ideas Put Into Practice – Combination Therapies in Lung Cancer

Speaker to Be Determined

2:00

Borrowing from the Military Strategy in Immunotherapy War
in Cancer

James Gulley, M.D., Ph.D.
Chief–Genitourinary Malignancies Branch;
Director–Medical Oncology Service
Center for Cancer Research, NIH

2:20

Immunosequencing in the Service of Immuno-oncology

 

Ilan "Lanny" Kirsch, M.D.
Senior Vice President–Translational Medicine
Adaptive Biotechnologies

2:40

Break

2:55

Title to Be Determined

John Lin, M.D., Ph.D.

Vice President, Immune Oncology & Head, Regeneron Bispecific R&D

Regeneron

3:15

Immunotherapy Combinations Panel Discussion

4:15

Reception


 

Speakers

 

 

Christoffel Boshoff, MD, Ph.D.

Senior Vice President, Immuno-Oncology, Early Development and Translational Oncology

Pfizer Inc.

 

Joshua Brody, M.D.

Director–Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai,

Hess Center for Science and Medicine

 

Timothy Chan M.D., Ph.D.

Vice Chair, Department of Radiation Oncology;

Director–Translational Oncology Division;

Member–Human Oncology & Pathogenesis Program;

Director–Immunogenomics and Precision Oncology Platform;

Paine Webber Chair in Cancer Genetics

Memorial Sloan Kettering Cancer Center

 

Deborah Charych, Ph.D.

Executive Director–Research and Development

Nektar Therapeutics

 

André Choulika, Ph.D.

Chief Executive Officer

Cellectis

 

Robert Coffman, Ph.D.

Senior Vice President and Chief Scientific Officer

Dynavax

 

Marco Davila, M.D., Ph.D.

Associate Member, Department of Blood and Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

 

Thomas W. Dubensky, Jr., Ph.D.

Chief Scientific Officer

Aduro Biotech

 

James Gulley, M.D., Ph.D.

Chief–Genitourinary Malignancies Branch;

Director–Medical Oncology Service

Center for Cancer Research, NIH

 

Eric Hedrick, M.D.

Clinical Advisor

BeiGene

 

Christian Hinrichs M.D.

Investigator, Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, Center for Cancer Research

National Cancer Institute

 

Christian Itin, Ph.D.

Chief Executive Officer

Autolus

Speakers

 

 

Michael Kalos, Ph.D.

Chief Scientific Officer, Cancer Immunobiology

Lilly Research Laboratories, Eli Lilly & Company

 

Ilan "Lanny" Kirsch, M.D.

Senior Vice President–Translational Medicine

Adaptive Biotechnologies

 

Jeffery Kutok, M.D., Ph.D.

Chief Scientific Officer

Infinity Pharmaceuticals

 

Helen Tayton-Martin, Ph.D.

Chief Operating Officer

Adaptimmune

 

John Lin, M.D., Ph.D.

Vice President, Immune Oncology & Head, Regeneron Bispecific R&D

Regeneron

 

Miriam Merad, M.D., Ph.D.

Professor of Medicine, Hematology, and Medical Oncology

Mount Sinai

 

Col. (ret.) George E. Peoples, M.D., FACS, MC, USA

Founder and CEO, Cancer Insight, LLC;

Director–Cancer Vaccine Development Program;

Professor of Surgery, Uniformed Services University;

Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center

 

Robert Sikorski, M.D., Ph.D.

Senior Vice President and Chief Medical Officer

Five Prime Therapeutics

 

David Spencer, Ph.D.

Chief Scientific Officer

Bellicum Pharmaceuticals

 

Robert Stein, M.D., Ph.D.

President–Research and Development and CSO

Agenus

 

Laura Vidal, M.D.

Senior Medical Director-Global Oncology & Hematology

INC Research

 

Jedd Wolchok, M.D., Ph.D.

Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma & Immunotherapeutics Service; Director–Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center; Associate Director–Ludwig Center for Cancer Immunotherapy; Member–Ludwig Cancer Research; Professor of Medicine, Weill Medical College of Cornell University